Chardan Capital Brokers Cut Earnings Estimates for REGENXBIO

REGENXBIO Inc. (NASDAQ:RGNX) – Research analysts at Chardan Capital cut their FY2025 earnings estimates for shares of REGENXBIO in a note issued to investors on Monday, March 24th. Chardan Capital analyst D. Gataulin now expects that the biotechnology company will post earnings per share of ($3.03) for the year, down from their prior estimate of ($1.39). Chardan Capital currently has a “Buy” rating and a $52.00 price target on the stock. The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. Chardan Capital also issued estimates for REGENXBIO’s FY2026 earnings at $4.87 EPS.

Several other equities research analysts have also issued reports on RGNX. Leerink Partners set a $24.00 price target on shares of REGENXBIO in a research note on Tuesday, March 18th. HC Wainwright dropped their target price on REGENXBIO from $36.00 to $34.00 and set a “buy” rating for the company in a research report on Monday, March 17th. Raymond James initiated coverage on REGENXBIO in a report on Friday, February 7th. They issued an “outperform” rating and a $27.00 price target on the stock. The Goldman Sachs Group cut REGENXBIO from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $38.00 to $14.00 in a report on Tuesday, February 11th. Finally, Morgan Stanley increased their target price on REGENXBIO from $22.00 to $24.00 and gave the stock an “overweight” rating in a research note on Friday, March 14th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, REGENXBIO has a consensus rating of “Moderate Buy” and a consensus price target of $32.78.

REGENXBIO Stock Down 0.1 %

Shares of RGNX opened at $8.20 on Thursday. REGENXBIO has a 52-week low of $5.62 and a 52-week high of $22.42. The company has a market cap of $410.71 million, a PE ratio of -1.63 and a beta of 1.35. The business has a fifty day moving average of $7.37 and a 200 day moving average of $8.82.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings data on Thursday, March 13th. The biotechnology company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.27) by $0.26. The business had revenue of $21.21 million during the quarter, compared to analyst estimates of $23.70 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%.

Hedge Funds Weigh In On REGENXBIO

Several institutional investors have recently made changes to their positions in RGNX. Redmile Group LLC lifted its stake in REGENXBIO by 7.1% in the third quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company’s stock worth $51,327,000 after acquiring an additional 323,100 shares during the period. JPMorgan Chase & Co. lifted its position in shares of REGENXBIO by 67.0% in the 4th quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company’s stock worth $31,975,000 after purchasing an additional 1,659,206 shares during the period. Millennium Management LLC lifted its position in shares of REGENXBIO by 406.3% in the 4th quarter. Millennium Management LLC now owns 1,322,344 shares of the biotechnology company’s stock worth $10,222,000 after purchasing an additional 1,061,187 shares during the period. Balyasny Asset Management L.P. boosted its stake in shares of REGENXBIO by 6.0% during the fourth quarter. Balyasny Asset Management L.P. now owns 1,187,102 shares of the biotechnology company’s stock valued at $9,176,000 after purchasing an additional 66,993 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in REGENXBIO by 1.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,171,422 shares of the biotechnology company’s stock valued at $9,054,000 after buying an additional 21,234 shares during the period. Hedge funds and other institutional investors own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.